Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05750823 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT05750823 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 49 participants.
The verdict
NCT05750823, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas identified for treatment at baseline regardless of whether the area begins to improve or fully repigment.
Interventions
- DRUG Ruxolitinib Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2025-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05750823
The ClinicalTrials.gov registry entry for NCT05750823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib Cream is the first listed.
NCT05750823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05750823 about?
NCT05750823 is a clinical study titled "A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo". An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas identified for treatment at baseline...
What is the current status of trial NCT05750823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2023-04-11. Estimated completion is 2025-03-06.
What interventions are being tested in trial NCT05750823?
The interventions under investigation include: Ruxolitinib Cream (DRUG).
Who is sponsoring clinical trial NCT05750823?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.